The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.
For more than a decade, weve been able to approach multiple myeloma, in most cases, as a chronic disease treatable through long-term maintenance therapy. However, this disease has long been an outlier among cancer types.
Multiple myeloma is a primarily incurable disease but new treatment optionsparticularly newly approved cellular therapieshave opened the possibility for extending disease control for patients who would otherwise not have treatment options. As a result of these advances, we now have reason to move our eyes toward heightened goals of treatment.
Despite the availability of multiple treatment options, the majority of patients with multiple myeloma will have recurrent or progressive disease. Patients with newly diagnosed multiple myeloma who require therapy typically receive induction therapy with a combination of drugs to decrease tumor burden.
Multiple myeloma is a spectrum of disease. Monoclonal gammopathy of undetermined significance is an early plasma cell disorder that can progress to multiple myeloma or remain stable for years. Smoldering multiple myeloma is a more advanced form of early disease and may require therapy based on disease burden. Multiple myeloma requires induction therapy for patients who present with bone lesions, high serum calcium levels, renal insufficiency/ failure and anemia.1
Standard treatment for newly diagnosed multiple myeloma typically involves a combination of glucocorticoids, immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs) and monoclonal antibodies (mAbs).
To deepen remission, induction therapy can be followed by high-dose therapyusually with a melphalan-based treatment with autologous hematopoietic cell rescue, also known as autologous stem cell transplant. After transplant, patients typically receive maintenance therapy to prolong response to induction and high-dose therapy. An important consideration for patients who are eligible for transplant and elect to delay transplant is to have hematopoietic cells collected for future use.
Newly diagnosed patients with multiple myeloma who are transplant-ineligible patientsthose who are frail or have significant comorbiditiesshould receive induction therapy and once response is achieved continue treatment with dose-reduced therapy to maintain that favorable response.
For patients whose disease continues to progress after multiple lines of treatment, it becomes progressively difficult to control multiple myeloma that is resistant or refractory to approved therapies. The FDA approval of the first chimeric antigen receptor (CAR) T-cell therapy in March 2021 for the treatment of relapsed/ refractory multiple myeloma represented a significant advance2,3 (Snapshot2).
Idecabtagene vicleucel (ide-cel; Abecma), targets BCMA, which is expressed by malignant as well as normal plasma cells. It is approved for patients with relapsed/ refractory multiple myeloma after 4 or more prior lines of therapy, including treatment with an IMiD, a PI, and an anti-CD38 mAb.3
CAR T-cell therapy involves the insertion of a CAR into the T cell, targeting a cell surface molecule that is expressed by the myeloma cells. This form of gene therapy utilizes the T cell cytolytic capacity to target and eradicate the cancer cells.
The process involves using a patients own T cells for CAR insertion, which is achieved using a viral vector. The cells are obtained through leukapheresis, altered through insertion of the CAR and then expanded in the laboratory. The patient then undergoes lymphodepletion followed by infusion of these CAR-enhanced T cells. The lymphodepletion is thought to temporarily favor the expansion of the CAR T cells over the patients own T cells. The CAR T cells target myeloma cells, reducing tumor cell burden.
The toxicities associated with CAR T-cell products for multiple myeloma are similar to those of the CAR T products for lymphoma and include tumor lysis syndrome, cytokine release syndrome, and immune effector cell associated neurotoxicity syndrome. Other adverse effects include cytopenias as well as B cell aplasia, resulting in hypogammaglobulinemia because of the targeting of B cells. These toxicities can be managed but require early identification and treatment by the clinical team.
Other CAR T-cell products are being evaluated in clinical trials, including 2 at Roswell Park. The products our teams are investigating both target BCMA with different approaches to vector design and expansion in the laboratory. It remains to be deter-mined how successful these CAR T-cell products will be for long-term control of relapsed/refractory multiple myeloma; however, this is an exciting new therapy that can be offered to patients for whom who may not have many options left for control of the disease.
Our research team is devoted to understanding the biology of multi-ple myeloma as well as improving therapeutic outcomes. Maximilian Merz, MD, initiated a project using single-cell RNA sequencing on isolated malignant plasma cells as a postdoctoral research fellow at Roswell Park. The team behind that work observed that biopsies from standard bone marrow samples contained multiple myeloma cells that had important differences in molecular behavior when compared with multiple myeloma cells from osteolytic lesionsknowledge that will allow us to better understand the mechanisms of drug resistance that develop during multiple myeloma treatment. This research was presented during the 2020 American Society for Clinical Oncology Virtual Scientific Program and has been submitted for publication.4
Hemn Mohammadpour, DVM, PhD, a Roswell Park postdoctoral fellow in the laboratory of Elizabeth Repasky, PhD, is leading a proj-ect to characterize the immune cells in bone marrow and osteolytic lesions. This study is ongoing and will allow us to characterize the mechanisms by which local immune suppression occurs during the development and treatment of multiple myeloma.
Investigators at Roswell Park aim to also develop strategies to reverse immune dysfunction to prevent infections as well as control the endogenous immune response to multiple myeloma. Mohammadpour is investigating how myeloma tumors prevent the immune system from recognizing and eradicating the cancer. He has an interest in both allogeneic and endogenous tumor killingthe former during allogeneic hematopoietic cell therapy and the latter during tumor immunotherapy.
Mohammadpour is also pursuing novel strategies for allogeneic CAR T-cell therapy. This approach, which is under investigation, uses an allogeneic T cell, modified to express a CAR, to prevent rejection and to prevent alloreactivity by the T cell against the host.
Were proud to highlight these clinical, translational, and basic research projects because they all represent exciting opportunities to improve patient outcomes and provide novel therapies for our patients. Cellular therapies, along with promising new agents, will continue to allow us to develop strategies that will lead to long-term disease control and possibly cure.
Follow this link:
Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Biomedical Researcher Seeks to Improve Outcomes in Stem Cell Treatments - University of Arkansas Newswire - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Scalise returning to Washington next week with cancer in complete remission - The Hill - February 13th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 9th, 2024
Recent Comments